white or yellowish-white powder. almost odorless. combined with levodopa for Parkinson's disease and Parkinson's syndrome.
Sinemet,Merck Sharp and
Dohme,Italy,1974
Carbidopa ((S)-(-)-Carbidopa) monohydrate, a peripheral decarboxylase inhibitor, can be used for the research of Parkinson's disease. Carbidopa monohydrate is a selective aryl hydrocarbon receptor (AhR) modulator. Carbidopa monohydrate inhibits pancreatic cancer cell and tumor growth.
Carbidopa may be used as a pharmaceutical reference standard for the determination of the analyte in pharmaceutical formulations by chromatography techniques.
ChEBI: Carbidopa is the hydrate of 3-(3,4-dihydroxyphenyl)propanoic acid in which the hydrogens alpha- to the carboxyl group are substituted by hydrazinyl and methyl groups (S-configuration). Carbidopa is a dopa decarboxylase inhibitor, so prevents conversion of levodopa to dopamine. It has no antiparkinson activity by itself, but is used in the management of Parkinson's disease to reduce peripheral adverse effects of levodopa. It has a role as an EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor, an antiparkinson drug, a dopaminergic agent and an antidyskinesia agent. It is a member of hydrazines, a hydrate, a monocarboxylic acid and a member of catechols. It contains a carbidopa (anhydrous).
Lodosyn (Bristol-Myers Squibb).
Muscle relaxant, Antiparkinsonian
Carbidopa, (S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid, is a whitecrystalline powder, slightly soluble in water (pKa＝7.8).Carbidopa is absorbed slower than levodopa and is 36%plasma protein bound.Carbidopa is metabolized to twomain metabolites (α-methyl-3-methoxy-4-hydroxyphenylpropionicacid and α-methyl-3,4-dihydroxyphenylpropionicacid). These two metabolites are primarily eliminated in theurine unchanged or as glucuronide conjugates. Unchangedcarbidopa accounts for 30% of the total urinary excretion.No drug interactions have been described.
